111 related articles for article (PubMed ID: 12677089)
1. MUC1 serum assays in breast cancer: tumor specificities and reference levels.
Bjerner J; Norum LF; Nilsson O; Nustad K
Tumour Biol; 2002; 23(6):315-23. PubMed ID: 12677089
[TBL] [Abstract][Full Text] [Related]
2. Carcinoma-associated MUC1 detected by immunoradiometric assays.
Norum LF; Varaas T; Kierulf B; Nustad K
Tumour Biol; 1998; 19 Suppl 1():134-46. PubMed ID: 9422099
[TBL] [Abstract][Full Text] [Related]
3. New immunoassays for MUC1 in breast cancer.
Norum LF; Sauren AM; Rye PD; Nustad K
Tumour Biol; 2001; 22(4):216-22. PubMed ID: 11399946
[TBL] [Abstract][Full Text] [Related]
4. Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer.
Tang Y; Cui X; Xiao H; Qi S; Hu X; Yu Q; Shi G; Zhang X; Gu J; Yu Y; Wang L; Li Y
Mol Med Rep; 2017 May; 15(5):2659-2664. PubMed ID: 28447743
[TBL] [Abstract][Full Text] [Related]
5. Quantification of MUC1 in breast cancer patients. A method comparison study.
Bon GG; van Kamp GJ; Verstraeten RA; von Mensdorff-Pouilly S; Hilgers J; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 1999 Mar; 83(1):67-75. PubMed ID: 10221613
[TBL] [Abstract][Full Text] [Related]
6. Automated immunofluorometric assay for MUC1.
Norum LF; Nilsson O; Nustad K
Tumour Biol; 2001; 22(3):169-75. PubMed ID: 11275795
[TBL] [Abstract][Full Text] [Related]
7. Cross-reactivity between MUC1 antigen and MCA: false elevation of serum CA 15-3 level in pregnant and lactating women by Ma695-Ma552-based assay.
Liang G; Fang X; Lin X; Feng X; Lu H; Wan Y; Gu Z
Breast Cancer Res Treat; 2018 Jun; 169(2):341-347. PubMed ID: 29396666
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1).
Isla Larrain M; Demichelis S; Crespo M; Lacunza E; Barbera A; Cretón A; Terrier F; Segal-Eiras A; Croce MV
J Exp Clin Cancer Res; 2009 Aug; 28(1):121. PubMed ID: 19715603
[TBL] [Abstract][Full Text] [Related]
9. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer marker Ca549. A multicenter study.
Chan DW; Beveridge RA; Bhargava A; Wilcox PM; Kennedy MJ; Schwartz MK
Am J Clin Pathol; 1994 Apr; 101(4):465-70. PubMed ID: 8160638
[TBL] [Abstract][Full Text] [Related]
11. Expression of mucin 1 possessing a 3'-sulfated core1 in recurrent and metastatic breast cancer.
Ideo H; Hinoda Y; Sakai K; Hoshi I; Yamamoto S; Oka M; Maeda K; Maeda N; Hazama S; Amano J; Yamashita K
Int J Cancer; 2015 Oct; 137(7):1652-60. PubMed ID: 25787775
[TBL] [Abstract][Full Text] [Related]
12. Tissue and serum MUC1 mucin detection in breast cancer patients.
Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of serum c-erbB-2 protein in breast cancer patients.
Willsher PC; Beaver J; Pinder S; Bell JA; Ellis IO; Blamey RW; Robertson JF
Breast Cancer Res Treat; 1996; 40(3):251-5. PubMed ID: 8883967
[TBL] [Abstract][Full Text] [Related]
15. Use of CA15‑3 for screening breast cancer: An antibody‑lectin sandwich assay for detecting glycosylation of CA15‑3 in sera.
Choi JW; Moon BI; Lee JW; Kim HJ; Jin Y; Kim HJ
Oncol Rep; 2018 Jul; 40(1):145-154. PubMed ID: 29749490
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.
Tang Y; Wang L; Zhang P; Wei H; Gao R; Liu X; Yu Y; Wang L
Clin Vaccine Immunol; 2010 Dec; 17(12):1903-8. PubMed ID: 20876819
[TBL] [Abstract][Full Text] [Related]
17. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System.
Molina R; Gion M; Gressner A; Troalen F; Auge JM; Holdenrieder S; Zancan M; Wycislo M; Stieber P
Clin Chem Lab Med; 2008; 46(5):612-22. PubMed ID: 18598203
[TBL] [Abstract][Full Text] [Related]
18. Assessment of five serum marker assays in patients with advanced breast cancer treated with medroxyprogesterone acetate.
Murray A; Clinton O; Earl H; Price M; Moore A
Eur J Cancer; 1995 Sep; 31A(10):1605-10. PubMed ID: 7488409
[TBL] [Abstract][Full Text] [Related]
19. Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study.
Bjerner J; Høgetveit A; Wold Akselberg K; Vangsnes K; Paus E; Bjøro T; Børmer OP; Nustad K
Scand J Clin Lab Invest; 2008; 68(8):703-13. PubMed ID: 18609108
[TBL] [Abstract][Full Text] [Related]
20. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
